EGFR and neoplasm: SRI31215, a novel inhibitor of pro-HGF activation, blocked signaling between tumor-promoting fibroblasts and colon cancer cells and overcame fibroblast-mediated resistance to EGFR inhibitors in colon cancer cells [30, 36].